Hva skjedde på GF 11.04.2024
Selskapet vakler videre med en ledelse som gulper opp det samme om og om igjen. Ingen visjoner eller målsetting. Hva skulle aksjonær gruppen som ba om fullmakt bidra til på GF?
«Støttegruppen» virker som et spill for galleriet uten mål og mening fra en av valkomiteen’s medlemmer som bare villedet intetanende aksjonærer til å støtte den videre drift uten mål og mening.
Når kommer rednings emisjon på 0,10kr med warrants i etterkant ?
Heldige alle som fikk solgt i går morges….
https://kommunikasjon.ntb.no/ir-files/17848634/3018/4299/Minutes%20from%20ordinary%20general%20meeting%202024.pdf
«Støttegruppen» virker som et spill for galleriet uten mål og mening fra en av valkomiteen’s medlemmer som bare villedet intetanende aksjonærer til å støtte den videre drift uten mål og mening.
Når kommer rednings emisjon på 0,10kr med warrants i etterkant ?
Heldige alle som fikk solgt i går morges….
https://kommunikasjon.ntb.no/ir-files/17848634/3018/4299/Minutes%20from%20ordinary%20general%20meeting%202024.pdf
Redigert 14.04.2024 kl 21:53
Du må logge inn for å svare
BioBull
21.04.2024 kl 16:40
529
I dette selskapet hersker grådighetskultur av verste sort. Ledelsen krafser til seg selv uten å levere resultater til de øvrige aksjonærer 2 ganger på samme dag...
Aksjonærene som stemte for dette forslaget kan bare takke seg selv for at ledelsen vanner ut alle øvrige aksjonærer.
1. Issuance of shares to members of the board
21.4.2024 12:17:53 CEST | Thor Medical ASA | Mandatory notification of trade primary insiders
Reference is made to the stock exchange announcement made by Nordic Nanovector ASA (now Thor Medical ASA, the "Company") on 3 July 2023 regarding grant of restricted share units ("RSU") to the members of the board.
The Company's board of directors has on 19 April 2024 resolved to issue 1,320,469 new shares in the Company towards the current members of the board pursuant to the RSU-program, of which 486,489 new shares have been issued to Ludvik Sandes, and 416,990 have been issued to each of John Andersen and Mimi Kristine Berdal
2. Grant of restricted stock units (RSU) to the members of the board
21.4.2024 12:20:17 CEST | Thor Medical ASA | Additional regulated information required to be disclosed under the laws of a member state
Reference is made to the stock exchange announcement made by Thor Medical ASA (the "Company") the Company on 11 April 2024 whereby it was disclosed that the Company's annual meeting resolved ("AGM"), among other things, the approval of a restricted share units ("RSU") program.
At the AGM, the shareholders approved the remuneration to the Company's current board of directors whereby the board members were given the choice to receive their remuneration, or a part thereof, for the period from the AGM to the annual general meeting of 2025, in the form of restricted share units ("RSU"), as a part of the Company's RSU program.
Each board member had the following three alternatives:
• Receive 100 % of the board remuneration in the form of RSUs;
• Receive 1/3 of the board remuneration in cash and 2/3 in the form of RSUs; or
• Receive 2/3 of the of the board remuneration in cash and 1/3 in the form of RSUs.
The board members have on 19 April 2024 notified the Company that they have chosen to receive 100 % of their board remuneration in the form of RSU's. The allocation is set out below:
Ludvik Sandnes, chairman of the board of directors, has been granted 401,938 RSUs;
John Andersen, board member, has been granted 344,518 RSUs; and
Mimi Kristine Berdal, has been granted 344,518 RSUs
The number of RSUs allocated to each board member has been determined based on the NOK value for the RSU-selected portion of the total compensation for the board member, divided by the volume weighted average share price of the 10 trading days prior to the grant date less the nominal value of the share.
The exercise of the RSUs is subject to, among other things, the respective board member being a part of the board of directors following the ordinary general meeting of 2025.
Aksjonærene som stemte for dette forslaget kan bare takke seg selv for at ledelsen vanner ut alle øvrige aksjonærer.
1. Issuance of shares to members of the board
21.4.2024 12:17:53 CEST | Thor Medical ASA | Mandatory notification of trade primary insiders
Reference is made to the stock exchange announcement made by Nordic Nanovector ASA (now Thor Medical ASA, the "Company") on 3 July 2023 regarding grant of restricted share units ("RSU") to the members of the board.
The Company's board of directors has on 19 April 2024 resolved to issue 1,320,469 new shares in the Company towards the current members of the board pursuant to the RSU-program, of which 486,489 new shares have been issued to Ludvik Sandes, and 416,990 have been issued to each of John Andersen and Mimi Kristine Berdal
2. Grant of restricted stock units (RSU) to the members of the board
21.4.2024 12:20:17 CEST | Thor Medical ASA | Additional regulated information required to be disclosed under the laws of a member state
Reference is made to the stock exchange announcement made by Thor Medical ASA (the "Company") the Company on 11 April 2024 whereby it was disclosed that the Company's annual meeting resolved ("AGM"), among other things, the approval of a restricted share units ("RSU") program.
At the AGM, the shareholders approved the remuneration to the Company's current board of directors whereby the board members were given the choice to receive their remuneration, or a part thereof, for the period from the AGM to the annual general meeting of 2025, in the form of restricted share units ("RSU"), as a part of the Company's RSU program.
Each board member had the following three alternatives:
• Receive 100 % of the board remuneration in the form of RSUs;
• Receive 1/3 of the board remuneration in cash and 2/3 in the form of RSUs; or
• Receive 2/3 of the of the board remuneration in cash and 1/3 in the form of RSUs.
The board members have on 19 April 2024 notified the Company that they have chosen to receive 100 % of their board remuneration in the form of RSU's. The allocation is set out below:
Ludvik Sandnes, chairman of the board of directors, has been granted 401,938 RSUs;
John Andersen, board member, has been granted 344,518 RSUs; and
Mimi Kristine Berdal, has been granted 344,518 RSUs
The number of RSUs allocated to each board member has been determined based on the NOK value for the RSU-selected portion of the total compensation for the board member, divided by the volume weighted average share price of the 10 trading days prior to the grant date less the nominal value of the share.
The exercise of the RSUs is subject to, among other things, the respective board member being a part of the board of directors following the ordinary general meeting of 2025.
Redigert 21.04.2024 kl 16:49
Du må logge inn for å svare
BioBull
23.04.2024 kl 22:58
297
Ekkelt :
Share option grant
23.4.2024 17:00:00 CEST | Thor Medical ASA | Mandatory notification of trade primary insiders
Thor Medical ASA (the "Company") has granted share options to employees and senior management.
The Company has today issued 4 800 000 share options, equal to 1.99% of total shares in the Company, to senior management at an exercise price at NOK 1.0822. The options are granted in accordance with the Company's guidelines for remuneration of senior executives and board members, as approved by Thor Medical's annual general meeting held 11 April 2024.
Each option provides a right to acquire one share at the exercise price, equal to the volume-weighted share price over the last ten trading days prior to grant. 1.600.000 of the share options will vest 12 months after the grant day, while the remaining share options will vest over the next 24 months with 133.333 options on the last day of each month following the initial vesting. The share options need to be exercised no later than five years after the initial award. The total gross benefit for exercised share options under this grant shall be limited to the grantee's total base salary of the three-year period.
2.700.000 share options were granted to Sindre Hassfjell, Chief Technological Officer, and 2.100.000 share options were granted to Astrid Liland, Vice President EHS, both being primary insider in the Company. Primary insider notifications pursuant to the market abuse regulation article 19 is attached.